A small study presented at The Endocrine Society meeting showed young type 1 diabetes patients with high LDL cholesterol levels who took atorvastatin attained significant reductions in non-HDL cholesterol levels at six months, while those in the placebo group showed slightly elevated levels. Researchers noted higher A1C rates in the atorvastatin group at three months but did not find A1C differences between the groups at six months.

Related Summaries